Actionable news
0
All posts from Actionable news
Actionable news in UNH: UNITEDHEALTH GROUP INCORPORATED,

Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment

Back on October 6, Duchenne Muscular Dystrophy (DMD) treatment advocate Jenn McNary

on Twitter that Humana Inc (NYSE: HUM) had approved 100 percent coverage for a patient wanting access to Sarepta Therapeutics Inc (NASDAQ: SRPT) muscular dystrophy drug eteplirsen - marketed as EXONDYS 51. This sparked a rush by stakeholders to confirm with other big insurers whether they would extend coverage for the drug.

Announcements Abound

Exondys 51 struggled for years to achieve FDA approval. Though accelerated approval finally came earlier this fall, to the delight of its supporters, the drug is not without its detractors.

Cigna Corporation (NYSE: CI) was the first company whose coverage of the drug was confirmed in September for patients with a confirmed mutation of a specific section of the DMD gene.

The morning after McNary's Humana tweet saw both an announcement from Anthem Inc (NYSE: ANTM) that it...


More